ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
April 17 2014 - 4:20PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology
company that develops novel anticancer therapeutics using its
antibody-drug conjugate (ADC) technology, today announced that the
Company will host a conference call at 8:00 a.m. ET on Friday,
April 25, 2014, to discuss ImmunoGen's financial results for the
three-month period ended March 31, 2014. Management also will
provide an update on the Company.
To access the live call by phone, dial
913-312-0376; the passcode is 4427468. The call also may be
accessed through the Investor Information section of the Company's
website, www.immunogen.com. Following the live webcast, a replay of
the call will be available at the same location through May 9,
2014.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer
therapeutics. The Company’s ADC technology uses tumor-targeting
antibodies to deliver an ImmunoGen cell-killing agent specifically
to cancer cells; the Company has also developed antibodies with
anticancer activity of their own. The first product approved with
ImmunoGen’s ADC technology is Roche’s Kadcyla®. ImmunoGen has three
wholly owned product candidates in clinical testing with additional
compounds in the clinic through the Company’s partnerships with
Amgen, Bayer HealthCare, Biotest and Sanofi. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
Genentech, Inc., a member of the Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024